BiotechTube

Epoetin Alfa + Roxadustat

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

CKD Anemia in Stable Dialysis Patients

Conditions

CKD Anemia in Stable Dialysis Patients

Trial Timeline

Jan 15, 2015 → Sep 19, 2018

NCT ID
NCT02273726

About Epoetin Alfa + Roxadustat

Epoetin Alfa + Roxadustat is a phase 3 stage product being developed by Astellas Pharma for CKD Anemia in Stable Dialysis Patients. The current trial status is completed. This product is registered under clinical trial identifier NCT02273726. Target conditions include CKD Anemia in Stable Dialysis Patients.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT02273726Phase 3Completed

Competing Products

20 competing products in CKD Anemia in Stable Dialysis Patients

See all competitors
ProductCompanyStageHype Score
Aranesp®AmgenApproved
84
KER-047Keros TherapeuticsPhase 2
44
LY2787106Eli LillyPhase 1
33
R744 + R744Chugai PharmaceuticalPhase 3
77
epoetin beta + placeboChugai PharmaceuticalPhase 3
77
recombinant human erythropoietin + recombinant human erythropoietin placeboChugai PharmaceuticalPhase 3
77
recombinant human erythropoietin + recombinant human erythropoietinChugai PharmaceuticalPhase 3
77
darbepoetin alfaAmgenPhase 3
76
PrasugrelDaiichi SankyoPhase 1
33
Prasugrel + PlaceboDaiichi SankyoPhase 2
52
roxadustatAstellas PharmaPhase 3
77
roxadustatAstellas PharmaPhase 3
77
Roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
77
AlefaceptAstellas PharmaPhase 1
33
RoxadustatAstellas PharmaPhase 2
52
roxadustatAstellas PharmaPhase 1
33
Roxadustat + PlaceboAstellas PharmaPhase 3
77
RoxadustatAstellas PharmaPre-clinical
23
Roxadustat + Epoetin AlfaAstellas PharmaPhase 3
77
roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
77

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85